Literature DB >> 1319063

Nonrandom integration of retroviral DNA in vitro: effect of CpG methylation.

Y Kitamura1, Y M Lee, J M Coffin.   

Abstract

We have developed a PCR-based system that allows us to assess the relative frequency of use of specific bases as targets for the avian leukosis virus in vitro integration system. Using this system, we tested the effect of 5-methylation of cytosine in runs of CpG on the distribution of integration target sites. We found that the distribution of preferred integration sites was not uniform along the target DNA; rather, there was a distinct and reproducible pattern of frequently used sites. This pattern was independent of orientation of the integrated DNA, and of overall structure and sequence of the target and fragment amplified. Methylation did not inhibit integration into CpG dinucleotides; on the contrary, this modification created highly preferred targets within runs of alternating CpG. Finally, similar but not identical specificity was observed by using preintegration complexes in infected extracts or purified integrase and DNA as enzyme and substrate. Thus, most of the specificity observed is conferred by interaction of integrase and targets, although it may be modified by other viral and/or cellular components.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1319063      PMCID: PMC49326          DOI: 10.1073/pnas.89.12.5532

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex.

Authors:  C M Farnet; W A Haseltine
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

2.  Relationship of avian retrovirus DNA synthesis to integration in vitro.

Authors:  Y M Lee; J M Coffin
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

3.  Ty3 integrates within the region of RNA polymerase III transcription initiation.

Authors:  D L Chalker; S B Sandmeyer
Journal:  Genes Dev       Date:  1992-01       Impact factor: 11.361

4.  Transcriptionally active genome regions are preferred targets for retrovirus integration.

Authors:  U Scherdin; K Rhodes; M Breindl
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

5.  Highly preferred targets for retrovirus integration.

Authors:  C C Shih; J P Stoye; J M Coffin
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

6.  Retrovirus integration and chromatin structure: Moloney murine leukemia proviral integration sites map near DNase I-hypersensitive sites.

Authors:  H Rohdewohld; H Weiher; W Reik; R Jaenisch; M Breindl
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

Review 7.  Specificity of restriction endonucleases and DNA modification methyltransferases a review (Edition 3).

Authors:  C Kessler; V Manta
Journal:  Gene       Date:  1990-08-16       Impact factor: 3.688

8.  The IN protein of Moloney murine leukemia virus processes the viral DNA ends and accomplishes their integration in vitro.

Authors:  R Craigie; T Fujiwara; F Bushman
Journal:  Cell       Date:  1990-08-24       Impact factor: 41.582

9.  Cloning, characterization, and expression in Escherichia coli of the gene coding for the CpG DNA methylase from Spiroplasma sp. strain MQ1(M.SssI).

Authors:  P Renbaum; D Abrahamove; A Fainsod; G G Wilson; S Rottem; A Razin
Journal:  Nucleic Acids Res       Date:  1990-03-11       Impact factor: 16.971

10.  Effects of methylation on a synthetic polynucleotide: the B--Z transition in poly(dG-m5dC).poly(dG-m5dC).

Authors:  M Behe; G Felsenfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

View more
  43 in total

1.  Substrate sequence selection by retroviral integrase.

Authors:  H Zhou; G J Rainey; S K Wong; J M Coffin
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Monoclonal antibodies against the minimal DNA-binding domain in the carboxyl-terminal region of human immunodeficiency virus type 1 integrase.

Authors:  T Ishikawa; N Okui; N Kobayashi; R Sakuma; T Kitamura; Y Kitamura
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Isolation and analysis of retroviral integration targets by solo long terminal repeat inverse PCR.

Authors:  Yi Feng Jin; Toshio Ishibashi; Akio Nomoto; Michiaki Masuda
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

4.  Relationship between retroviral DNA integration and gene expression.

Authors:  J B Weidhaas; E L Angelichio; S Fenner; J M Coffin
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  An amino acid in the central catalytic domain of three retroviral integrases that affects target site selection in nonviral DNA.

Authors:  Amy L Harper; Malgorzata Sudol; Michael Katzman
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

6.  Relationship between retroviral DNA-integration-site selection and host cell transcription.

Authors:  Lori F Maxfield; Camilla D Fraize; John M Coffin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-19       Impact factor: 11.205

7.  Division of labor within human immunodeficiency virus integrase complexes: determinants of catalysis and target DNA capture.

Authors:  Tracy L Diamond; Frederic D Bushman
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

8.  Differential selection of cells with proviral c-myc and c-erbB integrations after avian leukosis virus infection.

Authors:  M Gong; H L Semus; K J Bird; B J Stramer; A Ruddell
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Concerted integration of linear retroviral DNA by the avian sarcoma virus integrase in vitro: dependence on both long terminal repeat termini.

Authors:  A Aiyar; P Hindmarsh; A M Skalka; J Leis
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Retroviral integration: in vitro host site selection by avian integrase.

Authors:  M L Fitzgerald; D P Grandgenett
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.